2,586 Shares in Penumbra, Inc. $PEN Acquired by R Squared Ltd

R Squared Ltd bought a new position in shares of Penumbra, Inc. (NYSE:PEN) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 2,586 shares of the company’s stock, valued at approximately $849,000.

A number of other large investors also recently bought and sold shares of the stock. Hsbc Holdings PLC raised its holdings in Penumbra by 2.3% in the 4th quarter. Hsbc Holdings PLC now owns 1,527 shares of the company’s stock worth $475,000 after purchasing an additional 35 shares during the period. Farther Finance Advisors LLC grew its position in shares of Penumbra by 27.1% in the fourth quarter. Farther Finance Advisors LLC now owns 178 shares of the company’s stock valued at $55,000 after purchasing an additional 38 shares during the period. Swiss Life Asset Management Ltd increased its stake in shares of Penumbra by 2.3% during the fourth quarter. Swiss Life Asset Management Ltd now owns 1,728 shares of the company’s stock worth $537,000 after purchasing an additional 39 shares in the last quarter. Keybank National Association OH lifted its stake in Penumbra by 1.2% in the 4th quarter. Keybank National Association OH now owns 3,705 shares of the company’s stock valued at $1,152,000 after buying an additional 43 shares in the last quarter. Finally, UMB Bank n.a. lifted its position in shares of Penumbra by 11.3% in the fourth quarter. UMB Bank n.a. now owns 442 shares of the company’s stock valued at $137,000 after acquiring an additional 45 shares in the last quarter. 88.88% of the stock is owned by institutional investors and hedge funds.

Penumbra Stock Up 0.0%

NYSE:PEN traded up $0.14 during midday trading on Tuesday, hitting $318.37. 119,309 shares of the company were exchanged, compared to its average volume of 734,774. The company has a fifty day simple moving average of $321.32 and a 200 day simple moving average of $329.68. The company has a current ratio of 6.02, a quick ratio of 3.95 and a debt-to-equity ratio of 0.01. Penumbra, Inc. has a fifty-two week low of $221.26 and a fifty-two week high of $362.41. The company has a market capitalization of $12.52 billion, a PE ratio of 73.36, a price-to-earnings-growth ratio of 1.97 and a beta of 0.70.

Penumbra (NYSE:PEN) last announced its earnings results on Wednesday, May 6th. The company reported $0.82 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.06 by ($0.24). Penumbra had a net margin of 11.76% and a return on equity of 10.87%. The firm had revenue of $374.76 million during the quarter, compared to analyst estimates of $370.47 million. During the same period last year, the company earned $0.83 earnings per share. The firm’s revenue for the quarter was up 15.6% compared to the same quarter last year. As a group, equities analysts anticipate that Penumbra, Inc. will post 5.04 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the stock. Citigroup decreased their price target on shares of Penumbra from $374.00 to $350.00 and set a “neutral” rating on the stock in a research note on Thursday, May 7th. Royal Bank Of Canada reaffirmed a “sector perform” rating and issued a $374.00 price target on shares of Penumbra in a research note on Thursday, June 11th. Zacks Research downgraded shares of Penumbra from a “hold” rating to a “strong sell” rating in a report on Monday, June 29th. Wall Street Zen upgraded shares of Penumbra to a “hold” rating in a research note on Saturday, May 9th. Finally, Evercore reaffirmed an “outperform” rating and set a $320.00 price objective on shares of Penumbra in a research report on Monday. Three analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $360.33.

Penumbra Company Profile

Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra’s technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.

At the core of Penumbra’s portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases.